Global Blood Therapeutics announced the U.S. FDA has granted accelerated approval for Oxbryta (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older. Oxbryta is expected to be available through GBT’s specialty pharmacy partner network within two weeks.
The accelerated approval of Oxbryta was based on data from the Phase 3 HOPE Study (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) which enrolled 274 patients 12 years of age and older with SCD. Data showed clinically meaningful and statistically significant improvements in hemoglobin levels, accompanied by reductions in red blood cell destruction (hemolysis). After 24 weeks of treatment, 51.1% of patients receiving Oxbryta achieved a greater than 1 g/dL increase in hemoglobin compared with 6.5% receiving placebo. The most common adverse reactions occurring in ≥10% of patients treated with Oxbryta with a difference of >3% compared to placebo were headache, diarrhea, abdominal pain, nausea, fatigue, rash and pyrexia.
The FDA instituted its accelerated approval pathway to allow for earlier approval of drugs that treat serious conditions and that f...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).